Novo Nordisk under pressure

Novo Nordisk: CagriSema Disappoints Again
Novo Nordisk A/S's CagriSema faces challenges, yet new trials aim to enhance efficacy, rival Eli Lilly in obesity treatments, and stay competitive. Click for more.
Novo Nordisk under pressure as obesity drug disappoints in diabetes trial
Shares of Novo Nordisk (NVO) are sliding in Monday trading after the company announces results for its trial of weight-loss drug CagriSema.
Novo Nordisk's Combo Drug CagriSema Shows 16% Weight Reduction In Second Phase 3 Trial
Novo Nordisk's REDEFINE 2 trial shows CagriSema led to significant weight loss in patients with obesity and type 2 diabetes. Regulatory filing is planned for 2026.
Novo Nordisk Shares Fall After Latest CagriSema Obesity Drug Trial Results -- Update
Novo Nordisk shares fell after the pharmaceutical giant released fresh trial results for its CagriSema developmental weight-loss drug. The Danish company said CagriSema helped obese or overweight type 2 diabetics lose an average 15.
Novo Nordisk reports REDEFINE 2 trial of CagriSema achieved primary endpoint
Novo Nordisk (NVO) announced headline results from REDEFINE 2, a phase 3 trial in the global REDEFINE program. REDEFINE 2 is a 68-week efficacy
Novo Nordisk’s stock drops despite CagriSema hitting goal of Phase III trial
The Wegovy successor was able to meet its primary endpoint with a 15.7% weight loss among those dosed with the combination injectable.
MarketBeat on MSN4d
Despite Challenges Novo Nordisk Plans to Crush GLP-1 Competitors
Novo Nordisk A/S (NYSE: NVO) has declared that its GLP-1 drugs for chronic obesity, under the brands Ozempic and Wegovy, are ...
AbbVie Is Preparing To Challenge Eli Lilly And Novo Nordisk
AbbVie Inc. enters the obesity market with GUBamy, a promising amylin analog. Click here to find out why ABBV stock is a Buy.
Monthly Prescribing Reference10d
Novo Nordisk Provides Direct-to-Patient Delivery Option for Wegovy
Novo Nordisk is providing direct-to-patient delivery ... Wegovy, a glucagon-like peptide-1 (GLP-1) receptor agonist, is indicated in combination with a reduced calorie diet and increased ...
Yahoo Finance8d
Novo Nordisk cuts Wegovy price through new direct-to-patient online pharmacy
Novo Nordisk is introducing a direct-to-patient ... Novo is slashing the cost for all doses of its glucagon-like peptide-receptor agonist (GLP-1RA) to $499 per month, a hefty discount to the ...